Symbol
| AKR1B1
| contributors: mct - updated : 24-08-2011
|
HGNC name
| aldo-keto reductase family 1, member B1 (aldose reductase)
|
HGNC id
| 381
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --over
|  
|
in the endometrium, during the menstrual cycle during the secretory phase and in both epithelial and stromal cells | tumoral
|  
|  
| --over
|  
|
over-expression in some types of hepatocellular carcinomas (HCCs) is (T3)receptor -dependent and might play a crucial role in the development of HCC | |
Susceptibility
|
not associated to susceptibility to diabete nephropathy to diabetic retinopathy in type 2 diabetes |
Variant & Polymorphism
other
| type-2 diabetics with the CC genotype at C(-106)T polymorphism were more susceptible for developing retinopathy as a result of chronic hyperglycemia than those with the CT or TT genotype |
|
|
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
reproduction | genital | | |
potential target for treatment of menstrual disorders | miscelleaneous | vascular | | |
inhibition of AK1B1 may be a useful therapeutic approach in preventing vascular complications | diabete | metabolic syndrom | | |
inhibition of AKR1B1 in diabetics may protect against damage in the brain and retina following ischemic reperfusion injury. | immunology | infectious | | |
inhibition of this enzyme may be useful to attenuate maladaptive host responses and to treat acute cardiovascular dysfunction associated with endotoxic shock |
| | | |
| deletion of Akr1b1 leads to less severe brain and retinal ischemic injuries in the diabetic db/db mouse | |
|